Drug Profile
Research programme: xeroderma pigmentosum group A protein inhibitors - NERx Biosciences
Alternative Names: NERx X80 class of compounds - NERx Biosciences; NERx-X80Latest Information Update: 20 Sep 2023
Price :
$50
*
At a glance
- Originator NERx Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action DNA repair inhibitors; DNA-binding protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 20 Sep 2023 Xeroderma pigmentosum group A protein inhibitors are still in preclinical development for Cancer in USA (NERx Biosciences pipeline, September 2023)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Cancer in USA
- 27 Sep 2016 Preclinical trials in Cancer in USA before September 2016 (NERx Bioscience pipeline, September 2016)